Some of the content on this page has been created using generative AI.
What is it about?
The study evaluates the prevalence and importance of preperitoneal vas deferens (VD) infiltration in high-risk prostate cancer (PCa) patients who underwent robot-assisted radical prostatectomy. The Briganti score, a measure of disease aggressiveness, had a median value of 19%. Distal VD infiltration was found in 20 patients (6%), while preperitoneal VD infiltration was detected in two patients (0.6%). The study found no association between distal VD infiltration and increased nodal disease or positive margins in pT3b patients. Both patients with preperitoneal VD infiltration had aggressive disease in advanced stages, with one patient experiencing nodal disease. The study emphasizes the rarity of preperitoneal VD infiltration and calls for further research to confirm its role in PCa recurrence.
Featured Image
Why is it important?
This research is important because it evaluates the prevalence and significance of preperitoneal vas deferens (VD) infiltration in high-risk prostate cancer (PCa) patients. It is crucial to understand the extent of VD infiltration as it may help in identifying aggressive tumors and improving treatment strategies. Key Takeaways: 1. The study analyzed 332 high-risk PCa patients who underwent robot-assisted radical prostatectomy. 2. Preperitoneal VD infiltration was found in two patients (0.6%), while distal VD infiltration was detected in 20 patients (6%). 3. Distal VD infiltration was not associated with increased chances of positive surgical margins or nodal status in pT3b patients. 4. Both patients with preperitoneal VD infiltration had aggressive disease in locally advanced stages and bilateral distal VD infiltration. 5. The study suggests that VD infiltration may be an intermediate step in rare cases of testicular recurrence. 6. Further robust data are required to confirm the hypothesis.
AI notice
Read the Original
This page is a summary of: Preperitoneal vas deferens infiltration in high‐risk prostate cancer, BJUI Compass, September 2023, Wiley,
DOI: 10.1002/bco2.289.
You can read the full text:
Contributors
Be the first to contribute to this page